Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 8 Documents

Search results for , issue "Vol 15, No 3 (2021): September" : 8 Documents clear

Quality of Life and Adherence to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia Patients at Dharmais Cancer Hospital Jakarta Nisha Virginia; Maksum Radji; Lucia Rizka Andalucia
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Quality of life and adherence to long-term imatinib mesylate (IM) therapy is a major factor in achieving therapeutic effects in patients with chronic myeloid leukemia (CML). However, the data of the quality of life and adherence level is inconsistent in various studies and is also not fully understood yet in Indonesia. Methods: This is an observational study (single-centered) using a cross-sectional design. CML patients older than 18 years old with National Health Insurance (JKN) at the Dharmais Cancer Hospital (RSKD) Jakarta who used IM for at least one month were tested using the Medication Adherence Questionnaire (MAQ) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) from March to April 2020.Result: A total of 50 CML patients were included in the study (male: female ratio = 1.08: 1), had a good median score of global health status/QoL, and had a good function and symptom scales, except for the fatigue symptom scale (median: 33.33; 25th percentile - 75th percentile: 11.11– 44.44). The patient adherence rate was dominated by adherent patients (20/50; 40.0%). Comparative analysis revealed that the scale of QoL (p = 0.028) and fatigue (p = 0.094) variables showed statistically significant differences between adherent and non-adherent subjects.Conclusions: This study showed that two-fifth of patients were considered to be non-adherent. Adherent patients were known to have higher QoL than non-adherent patients. Meanwhile, patients with severe symptoms of fatigue were found to be non-adherent to IM therapy.

Circulating Tumour DNA for Early Diagnosis of Pancreatic Ductal Adenocarcinoma Ayu Hutami Syarif
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Pancreatic ductal adenocarcinoma (PDAC) has been deathly cancer arising from pancreatic cells. Despite the improvement in the standard of diagnosis, most patients seek medical care in the late stage. Due to the aggressiveness of the disease, it is therefore imperative to detect the early lesion for a better outcome.Methods: We identified 416 articles relevant to circulating tumor DNA (ctDNA) and PDAC using predefined keywords in PubMed, PubMed Central, and Cochrane Library from January 1, 2011, to January 1, 2021 (10 years). Firstly, we screened the titles and abstracts, and 63 articles were included. Then, we screened those articles for the full-text version and included only 8 articles fulfilling our inclusion criteria. All steps were reviewed by the author.Results: The presence of ctDNA in the blood reflects the occurrence of the pancreatic cancerspecific mutation in the primary tumor. The detection of KRAS mutation in ctDNA and tumor samples is highly consistent. The number of positive findings in early-stage patients is low, in line with the low ctDNA concentration measured. However, the combination of KRAS detected in ctDNA and other biomarkers showed prominent results with higher sensitivity and specificity.Conclusions: ctDNA is a promising tool for early detection of PDAC. Despite its low positivity rate in certain studies, it is considerably concordant with the primary tumor. Future improvement in the technique application is required to overcome the issue of low DNA concentration in circulation.

Characteristics of Thyroid Cancer Patients in Haji Adam Malik General Hospital Rizka Annisa Harahap; Pimpin Utama Pohan; Sufitni Sufitni
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Thyroid cancer is the most common endocrine cancer, and its incidence has continuously increased in the last three decades all over the world. The national prevalence of thyroid cancer has not been recorded. Sex, obesity, and the size of thyroid nodules are the risk factors for thyroid cancer. The aim of this study is to acknowledge the characteristics of thyroid cancer patients in Haji Adam Malik General Hospital. Methods: This is a cross-sectional study and carried out among 97 patients with thyroid cancer at Haji Adam Malik General Hospital from 2013 until 2015. Secondary data were obtained by consecutive sampling techniques using medical records. The inclusion criteria are all patients diagnosed with thyroid cancer based on histopathological analysis. Data were analyzed descriptively using SPSS in percentage.Results: From 97 patients with thyroid cancer, it could be concluded that thyroid cancer is the most frequently diagnosed in the age group of 55–64 years (32.0%). Females were predominant that attributed to 71.1% than males (28.9%). The majority of thyroid cancer was diagnosed at stage IV (39.2%) with the most common histopathological feature of papillary thyroid carcinoma (46,4%). Thyroid cancer patients are usually found with normal BMI (37.1%) and nodule thyroid found with the diameter of ≥4cm (47.4%).Conclusions: In the 55–64-year age female group, thyroid cancer is most diagnosed at stage IV with papillary thyroid carcinoma. Thyroid cancer patients are usually found with normal BMI and the nodule size of ≥4 cm.

A Case Series of Spontaneous Chylothorax in Lymphoma Widiastuti Widiastuti; Eri Rakhmawati; Yusuf Syaeful Nawawi; Ana Rima
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Chylothorax is a rare condition originating from lymphatic system damage as an accumulation of chyle in the pleural space. It can be classified into spontaneous or non-traumatic, traumatic, and idiopathic. A spontaneous chylothorax is primarily caused by neoplasm, such as lymphoma.Case Presentation: Herein, we report two cases of chylothorax presenting as massive pleural effusion in two patients of a 23-year-old male with nodular sclerosis type Hodgkin’s lymphoma and a 31-year-old female with metastatic lymphadenopathy of undifferentiated carcinoma from non-Hodgkin’s lymphoma.Conclusion: A spontaneous chylothorax is a rare condition that may lead to a life-threatening event when it is not properly and promptly treated.

A Rare and Fatal Case of Cutaneous T-Cell Lymphoma (CTCL) Lia Sasmithae; Indra Perdana
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Cutaneous T-Cell Lymphoma (CTCL) is a form of Non-Hodgkin Lymphoma involving T-cell neoplasms mainly concentrated in the skin. Primary Cutaneous Peripheral T-Cell Lymphoma is Not Otherwise Specified (PTL-NOS) is the rarest case of CTCL disease.Case Presentation: A female, 35 years old, complained of a lump on her face. In the last 3 months, the lump felt soft, contained a liquid that, when it ruptures, secretes Blood, and the crusty scar will blacken and easily bleed with pain. Physical examination of pale conjunctiva on the face, neck, chest, abdomen, back, and legs obtained nodules with a chewy consistency with erythema appearance in varying size. Some nodules that appear were covered in blackish crustae. The right lung has a decrease in the sound of breath, accompanied by swelling in both limbs. The conclusion of bilateral femur skin biopsy impresses cutaneous T lymphoma cells. Within three months, cancer developed into lesions spread almost throughout the body, and due to the rapid and progressive nature of cancer, its diagnosis developed into PTL-NOS.Conclusions: Patients with PTL-NOS may come with solitary nodules such as red tumors in any area of the body. However, most often, patients come with symptoms of multifocal or diffuse scattered nodules. In enforcing the diagnosis, it takes a high level of suspicion, and multiple rebiopsies are necessary to enforce the diagnosis of CTCL.

Triple-Negative Breast Cancer Clinicopathology: A Single-Center Experience Dedy Hermansyah; Yolanda Rahayu; Arjumardi Azrah; Gracia Pricilia; Sufida Sufida; Denny Rifsal; Albiner Simarmata
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that does not have estrogen receptors, progesterone receptors, and HER-2 receptors. This subtype is found in 15-20% of all types of breast cancer, and it is often associated with a high recurrence rate and mortality after getting definitive therapy. The aim of our study is to investigate the clinicopathology of breast cancer in our center, where the majority were Bataknese.Methods: We evaluated the clinical and pathological characteristics of TNBC retrospectively from medical records data, from January 2017 to December 2019 with a total of 105 patients but only 79 patients had complete clinicopathological and immunohistochemistry data. This study was conducted in Murni Teguh Memorial Hospital, Medan, Indonesia. Results: From 79 TNBC patients, the average age at clinical presentation was 41-50 years group about 35 samples (44.3%). All patients had an invasive type of ductal carcinoma (100%). The majority of tumor size was T2 in 51 patients (64,6%), 83.6% grade 3 tumors. Both angioinvasion and lymph invasion were found in 48 patients (60.8%) while tumor-infiltrating lymphocyte (TIL) was found in 58 patients (73.4%), and 44 patients (55.7%) had lymph node metastases.Conclusions: According to some existing literature, TNBC showed more aggressive characteristics which are the same as our study. TNBC was diagnosed at young age, grade 3 tumors, having TIL which is very likely to occur distant metastases to lymph nodes.

Does Lack of EWSR1-ATF1 Fusion Exclude Diagnosis of Salivary Gland Clear Cell Carcinoma? Sibel Sensu; Nusret Erdogan; Kayhan Basak; Egzona Qipa; Murat Buyukdogan
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Ewing sarcoma breakpoint region 1- activating transcription factor 1 (EWSR1-ATF1) fusion is mentioned as a diagnostic marker in favor of clear cell carcinoma in the differential diagnosis of clear cell neoplasms of salivary glands. However, in literature, its positivity is reported between 82% and 93%. In salivary glands, various benign and malignant primary tumors, as well as odontogenic neoplasms and metastatic cases, present with a varied number of clear cells. Clear cell carcinoma of the salivary gland is a rare entity with distinct histochemistry and immunohistochemistry features.Case Presentation: We present a clear cell carcinoma of the salivary gland showing cytoplasmic Periodic acid–Schiff (PAS) (+), mucin (-) staining, cytokeratin (CK), CK7, and P63 immunoreactivity without EWSR1-ATF1 fusion. Conclusions: We conclude that clinical, morphological, and immunohistochemical analyses should be the guide for diagnosis even though molecular analysis does not support it.

Profile of Ovarian Cancer Patients In Mangusada Badung Regional Public Hospital I Gusti Ngurah Agung Trisnu Kamajaya; Bagus Ngurah Brahmantara; AA Ngurah Agung Putra Wirawan
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Ovarian cancer is still one of the neoplasms within the gynecology scope. Besides, World Health Organization (WHO) states that ovarian cancer ranks fourth cancer in women with the lowest five-year survival rate (43%). Thus, this research aims to recognize the risk factors in patients with ovarian cancer and the commonly found characteristic.Methods: This cross-sectional observational research on 29 women diagnosed with ovarian cancer observed the age, parity, body mass index (BMI), contraception, character, and stadium. The medical record samples based on patients’ registers were obtained from the Obstetrics and Gynecologic Polyclinic in Mangusada Badung Regional Public Hospital in the January–December 2019 period, and the result data were distributed using contingency tables. Results: The data dominantly diagnosed ovarian cancer, with age distribution 51-60 years (34.5%), 44.8% with obesity, 44.8% nullipara, without a history of contraceptive use, menarche within 12 years old (41.4%), diagnosed stage IIIC (42.3%), and with serous epithelial tumor subclassification (65.5%).Conclusions: Predominant ovarian cancer is found at a late stage. The most common risk factors of developing ovarian cancer, including the age of 51–60, obesity, menarche within 12 years old, and no history of hormonal contraceptive use, are consistent with this research hypothesis about risk factors dominantly found in patients with ovarian cancer

Page 1 of 1 | Total Record : 8

Filter by Year

2021 2021

Filter By Issues

All Issue Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA